trim46  (Proteintech)

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: TRIM46 expression is associated with DDP resistance in non-small cell lung cancer tissues. (A) Immunohistochemistry staining was performed using a TRIM46 antibody and normal, DDP-sensitive and DDP-resistant tissues. (B) Percentages of tissues with low or high TRIM46 expression in DDP-sensitive (n=38) or DDP-resistant (n=47) patients. (C) Percentages of patients with DDP-resistant or DDP-sensitive tissues and low (n=44) or high (n=41) TRIM46 expression. ***P<0.001. TRIM46, tripartite motif 46; DDP, cisplatin.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: TRIM46 upregulation contributes to DDP resistance in non-small cell lung cancer cells. (A) RT-qPCR (left) and western blot (right) analysis of TRIM46 expression in 16HBE, A549 and A549/DDP cells. (B) RT-qPCR (left) and western blot (right) analysis of TRIM46 expression in A549 cells infected with TRIM46 overexpression lentivirus. (C) Cell apoptosis was measured after transduction with TRIM46-overexpression lentivirus and/or DDP treatment (0, 5 and 10 µM) in A549 cells. (D) Quantitative analysis of cell apoptosis. (E) Representative images of the comet assay showing DNA fragmentation after transduction with TRIM46-overexpression lentivirus and/or DDP treatment (0, 5 and 10 µM) in A549 cells (scale bar, 50 µm; magnification, ×400). (F) Quantification of tail DNA (%) revealing DNA damage after transduction with TRIM46-overexpression lentivirus and/or DDP treatment (0, 5 and 10 µM) in A549 cells. *P<0.05, **P<0.01, ***P<0.001. TRIM46, tripartite motif 46; DDP, cisplatin; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; PI, propidium iodide.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Infection, Over Expression, Transduction, Single Cell Gel Electrophoresis, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: TRIM46 knockdown alleviates DDP resistance in non-small cell lung cancer cells. (A) Reverse transcription-quantitative polymerase chain reaction (left) and western blot (right) analysis of TRIM46 expression in A549/DPP cells infected with TRIM46 knockdown lentiviruses. (B) Cell apoptosis was measured after transduction with TRIM46 knockdown lentivirus and/or DDP treatment (0, 50 and 100 µM) in A549/DDP cells. (C) Quantitative analysis of cell apoptosis. (D) Representative images of the comet assay showing DNA fragmentation after transduction with TRIM46 knockdown lentivirus and/or DDP treatment (0, 50 and 100 µM) in A549/DDP cells (scale bar, 50 µm; magnification, ×400). (E) Quantification of tail DNA (%) revealing DNA damage after transduction with TRIM46 knockdown lentivirus and/or DDP treatment (0, 50 and 100 µM) in A549/DDP cells. ***P<0.001. TRIM46, tripartite motif 46; DDP, cisplatin; sh, short hairpin; NC, negative control; PI, propidium iodide.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Knockdown, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Expressing, Infection, Transduction, Single Cell Gel Electrophoresis, Negative Control

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: TRIM46 depletion inhibits cell proliferation by regulating the Akt signaling pathway. (A) Cell proliferation of A549/DDP cells transduced with TRIM46-knockdown lentiviruses. (B) Western blot analysis of p-Akt, Akt, caspase 3, cleaved-caspase 3 and RAD51 expression in A549/DDP cells transduced with TRIM46-knockdown lentiviruses. (C) Cell proliferation of A549 cells transduced with TRIM46-overexpression lentivirus and/or treated with LY294002 (20 µM) or vehicle. (D) Western blot analysis of p-Akt, Akt, caspase 3, cleaved-caspase 3 and RAD51 in A549 cells transduced with TRIM46-overexpression lentivirus and/or treated with LY294002 (20 µM) or vehicle. ***P<0.001 vs. shNC or Vector + Vehicle; ### P<0.001 vs. TRIM46 + Vehicle. TRIM46, tripartite motif 46; DDP, cisplatin; sh, short hairpin; NC, negative control; OD, optical density; p-, phosphorylated.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Transduction, Knockdown, Western Blot, Expressing, Over Expression, Plasmid Preparation, Negative Control

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: TRIM46 knockdown increases the sensitivity of xenograft tumors to DDP treatment. (A) Tumor volumes and (B) images of xenograft tumors in the designated groups (scale bar, 1 cm; n=6 per group). (C) TUNEL assay of xenograft tumor samples (scale bar, 100 µm; magnification, ×200). (D) Statistical analysis of the TUNEL assay (n=6 per group). (E) Western blot analysis of TRIM46 and RAD51 expression in xenograft tumors. ***P<0.001. TRIM46, tripartite motif 46; DDP, cisplatin; sh, short hairpin; NC, negative control.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Knockdown, TUNEL Assay, Western Blot, Expressing, Negative Control

Journal: Oncology Reports

Article Title: TRIM46 deficiency-induced DNA damage enhances the sensitivity of cisplatin in non-small cell lung cancer by regulating the Akt signaling pathway

doi: 10.3892/or.2026.9063

Figure Lengend Snippet: Mechanism of TRIM46 deficiency-induced DNA damage, enhancing the sensitivity of DDP in NSCLC by regulating Akt signaling pathway. (A) TRIM46 expression was positively associated with DDP resistance in NSCLC tissues. (B) TRIM46 overexpression significantly suppressed DDP-induced apoptosis and enhanced DDP resistance in A549 cells. (C) TRIM46 knockdown induced DNA damage by modulating the protein levels of p-AKT, RAD51, caspase 3, and cleaved-caspase 3, thereby resulting in cell proliferation inhibition in NSCLC cells. (D) TRIM46 knockdown increased the sensitivity of xenograft tumors to DDP treatment. NSCLC, non-small cell lung cancer; TRIM46, tripartite motif 46; DDP, cisplatin; p-, phosphorylated.

Article Snippet: The shRNA sequences targeting TRIM46 (shTRIM46-1, 5′-GGTGAGGATATGCAGACCT-3′; shTRIM46-2, 5′-GATATGCAGACCTTCACTT-3′; and shTRIM46-3, 5′-AGACCTTCACTTCCATCAT-3′), as well as the shNC (5′-GATACATACTAGATCGACT-3′) vector, were purchased from Shanghai GeneChem Co., Ltd and engineered into the pLKO.1 puro lentiviral vector (Addgene, Inc.).

Techniques: Expressing, Over Expression, Knockdown, Inhibition